基因工程时代的肿瘤浸润淋巴细胞疗法走向成熟
本文综述基因工程改造肿瘤浸润淋巴细胞(TIL)的临床前进展与正在进行的临床试验。2024年两项独立关键临床试验后TIL疗法获批,在难治性黑色素瘤中应答率高达50%;基因工程(病毒载体过表达细胞因子或嵌合受体、CRISPR-Cas9敲除PD-1和CISH等抑制基因)有望进一步提升TIL疗效与持久性,并拓展至更广泛实体瘤。
要点
- 2024年TIL疗法获批,难治性黑色素瘤应答率高达50%。
- 基因工程可过表达细胞因子或嵌合受体、敲除PD-1和CISH等抑制基因。
- 工程化TIL产品正在临床试验中评估,有望拓展至更广泛实体瘤。
核心结论
- 基因工程改造TIL有望提高疗效与持久性,并拓展至更广泛实体瘤。
研究设计与样本
- 综述,概述基因工程TIL的临床前进展与正在进行的临床试验。
主要发现
- 2024年两项独立关键临床试验后TIL疗法获批,成为难治性黑色素瘤的可行治疗选择,应答率高达50%。
- 病毒载体介导的细胞因子或嵌合受体过表达、CRISPR-Cas9等非病毒基因组编辑敲除PD-1和CISH等抑制基因,可进一步改善TIL疗效与持久性。
关键数值与推荐
- 难治性黑色素瘤中TIL疗法应答率高达50%。
临床怎么用
- TIL疗法已可作为难治性黑色素瘤的可行治疗选择。
- 基因工程TIL产品正在临床试验中评估,预期拓展个性化免疫治疗工具并改善更广泛实体瘤的持久结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advances in cancer immunotherapy from immune checkpoint modulation to adoptive cell transfer of tumour-infiltrating lymphocytes (TILs) have greatly improved outcomes for patients with advanced cancers, particularly metastatic melanoma. The approval of TIL therapy in 2024 following two independent landmark clinical trials has established this approach as a viable treatment option, with response rates of up to 50% in treatment-resistant melanoma. Genetic engineering offers new opportunities to further improve TIL efficacy and durability, including viral vector-mediated overexpression of cytokines or chimeric receptors, and non-viral genome editing techniques such as CRISPR-Cas9 to delete inhibitory genes such as PD-1 and CISH. In this Review we outline the current state of genetically engineered TILs, highlighting both preclinical advances and ongoing clinical trials. As these engineered products are evaluated in clinical settings, they are expected to expand the personalised immunotherapy toolkit and improve durable outcomes across a broader range of solid tumours.
引用
- Crowther MD, Sohlin JE, Svane IM, et al. Tumour-infiltrating lymphocyte therapy comes of age in the era of genetic engineering. Lancet Oncol. 2025. PMID: 41167225. doi:10.1016/S1470-2045(25)00434-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。